Suggested remit: To appraise the clinical and cost effectiveness of ciltacabtagene autoleucel within its marketing authorisation for treating relapsed and lenalidomide-refractory multiple myeloma after at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor.
- Status:
- Deferred
- Process:
- STA Standard
- ID number:
- 4012
- Deferred ID number:
- D5
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 July 2026 | Deferred. The evaluation of ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies is anticipated to commence in early July 2026 under a new ID number (GID‑TA12518). Following Johnson & Johnson’s prior decision to defer the submission to NICE, the topic will be closed under the current ID number (ID4012). |
| 08 May 2026 - 08 June 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 05 March 2026 | In progress. Following discussions with the company, this appraisal has been scheduled back into the work programme. The appraisal is expected to begin in early July 2026. |
| 08 March 2024 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 20 October 2023 | Note - Note added to the project documents |
| 12 April 2023 | Note - Note added to the project documents |
| 25 October 2022 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual